Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases

Contributed by: Business Wire

Logo

Tags

Biotechnology

FDA

Alternative Medicine

Health

Cannabis

Neurology

Pharmaceutical

Other Science

Mental Health

Research

General Health

Natural Resources

Science

Clinical Trials

Solid Dose Cannabinoid Medicines

More Like This

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases

Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances

(Photo: Business Wire)

ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

PR Newswire associated0

Tetra Pharm Technologies introduces pain relieving drug in the United Kingdom

Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar